Fig. 3: Distribution of antibody titers against SARS-CoV-2 based on age, severity scores, and presence of dyspnea.

These data represent samples collected from convalescent individuals (n = 175) during the first 140 days post-symptom onset (DPO). A Individuals <31 years of age have significantly lower IgG, IgM, and viral neutralizing antibody (VN) titers than those >40 years of age in this cohort (Ordinary one-way ANOVA, Tukey’s multiple comparison test; **P < 0.01; ***P < 0.001; ****P < 0.0001). Survival analysis of (B) VN, (C) IgG, and (D) IgM antibody titers during the first 140 DPO in convalescent individuals within the age groups of 20–30 (n = 95 samples) and >60 (n = 45 samples) (log-rank test, P > 0.05 for VN antibodies, *P < 0.05 for IgG and IgM). E Individuals with a severity score of 1 have significantly lower IgM and IgG titers than those above a score of 3 (Ordinary one-way ANOVA, Tukey’s multiple comparison test; **P < 0.01; ***P < 0.001; ****P < 0.0001). Survival analysis of (F) VN, (G) IgG, and (H) IgM antibody titers in relation to severity scores grouped as mild (1/2/3) and severe (4/5) in convalescent individuals during the first 140 DPO (log-rank test, *P < 0.05 for VN antibodies, P > 0.05 for IgG, ****P < 0.0001 for IgM). I Individuals with dyspnea had significantly higher VN, IgM, and IgG titers (unpaired t test, two-tailed; **P < 0.01; ****P < 0.0001). Survival analysis of (J) VN, (K) IgG, and (L) IgM antibody titers in relation to occurrence of dyspnea in convalescent individuals during the first 140 DPO (log-rank test, P > 0.05 for VN, P > 0.05 for IgG, ****P < 0.0001 for IgM).